TGFB1 and breast carcinoma: Interestingly, a tertiary lymphoid‐like structure was observed (red arrow), which has been reported to favor the outcome of immunotherapy.[26] It should be noted that IRE has also been used in the clinical and preclinical treatment of liver,[27] breast,[28] renal cancers,[29] etc. To test if our findings could extend to other tumor types, the treatment regimens were further evaluated in orthotopic 4T1 murine breast cancer model with a positive TGF‐β expression (Figure S5, Supporting Information).